Explore jobs
Find specific jobs
Explore careers
Explore professions
Best companies
Explore companies
DURECT revenue
DURECT's revenue is $2.0 million.
What is DURECT's revenue?
- DURECT's revenue growth from 2000 to 2024 is -35.63%.
- DURECT has 88 employees, and the revenue per employee ratio is $23,079.
- DURECT's peak quarterly revenue was $1.8M in 2024(q1).
- DURECT peak revenue was $53.1M in 2012.
- DURECT annual revenue for 2023 was 2.6M, -86.57% growth from 2022.
- DURECT annual revenue for 2024 was 2.0M, -21.58% growth from 2023.
On this page
Zippia finds jobs where you're a top candidate and applies on your behalf.
DURECT historical revenue
DURECT's peak revenue was $53.1M in 2012. The peak quarterly revenue was $1.8M in 2024(q1).
DURECT's revenue increased from $3.2m in 2000 to $2.0M currently. That's a -35.63% change in annual revenue.
DURECT annual revenue
DURECT annual revenue over time
| Fiscal year / year | DURECT revenue |
|---|---|
| 2009 | $24.5M |
| 2010 | $31.6M |
| 2011 | $33.5M |
| 2012 | $53.1M |
| 2013 | $15.3M |
| 2014 | $19.4M |
| 2015 | $19.1M |
| 2016 | $14.0M |
| 2017 | $36.7M |
| 2018 | $15.3M |
| 2019 | $25.1M |
| 2020 | $30.1M |
| 2021 | $14.0M |
| 2022 | $19.3M |
| 2023 | $2.6M |
| 2024 | $2.0M |
Rate DURECT's financial transparency
DURECT annual growth
DURECT saw the greatest revenue growth in 2017, when revenue increased by 161.46%.
DURECT had the lowest revenue growth in 2013, when revenue changed by -71.12%.
DURECT annual growth rate over time
| Year | DURECT growth |
|---|---|
| 2009 | -14%↓ |
| 2010 | 29%↑ |
| 2011 | 6%↑ |
| 2012 | 58%↑ |
| 2013 | -71%↓ |
| 2014 | 27%↑ |
| 2015 | -1%↓ |
| 2016 | -27%↓ |
| 2017 | 161%↑ |
| 2018 | -58%↓ |
| 2019 | 64%↑ |
| 2020 | 20%↑ |
| 2021 | -54%↓ |
| 2022 | 38%↑ |
| 2023 | -87%↓ |
| 2024 | -22%↓ |
DURECT jobs nearby
Do you work at DURECT?
Did DURECT meet its revenue projections?
DURECT financial information
| CEO | James Brown D.v.m |
| Industry | Pharmaceuticals, Biotechnology & Life Sciences |
| Company Type | Public |
| Employees Number | 88 |
| Date Founded | 1998 |
| Headquarters | Cupertino, California |
| Number of Locations | 3 |
| Revenue | $2.0M |
| Net Income | -$35,333,000 |
| Gross Proft | $2.0M (2024) |
| EBITDA | ($14.8M) (2005) |
| PE Ratio | -11.88 |
| Tax Rate | -0.0% |
| Market Capitalization | $98.9M |
| Total Assets | $60,100,000 |
| Ticker | DRRX |
DURECT jobs you might like
DURECT financing
DURECT received early financing of $20.0M on 2014-06-26.
| Series | Round size | Date |
|---|---|---|
| Post Ipo Equity | $20M | 06/2014 |
| Post Ipo Equity | $42.5M | 02/2021 |
DURECT investors
| Investors | Security type |
|---|---|
| Oxford Finance LLC | Post Ipo Equity |
DURECT competitors
DURECT's top competitor, Johnson & Johnson, earned an annual revenue of $88.8B.
DURECT's smallest competitor is Virpax Pharmaceuticals with revenue of $284.9K last year.
| Company name | Average salary | Revenue | Employee size | Job openings |
|---|---|---|---|---|
| Recro Pharma Inc. | $55,587 | $94.6M | 255 | - |
| PLx Pharma | $65,724 | $8.2M | 12 | - |
| Pacira BioSciences | $88,724 | $675.0M | 750 | 17 |
| Zogenix | $71,837 | $81.7M | 90 | - |
| Virpax Pharmaceuticals | $64,982 | $284.9K | 6 | - |
| Bellerophon Therapeutics | $45,248 | $5.6M | 17 | - |
| SpineThera | $45,112 | $5.0M | 9 | - |
| Delpor | $51,903 | $450,000 | 9 | - |
| Johnson & Johnson | $76,686 | $88.8B | 134,500 | 2,085 |
| Alcami | $70,250 | $87.0M | 981 | 59 |
Search for jobs
Related company revenues
Working at related companies
Related company jobs
DURECT highest paying jobs
Zippia gives an in-depth look into the details of DURECT, including salaries, political affiliations, employee data, and more, in order to inform job seekers about DURECT. The employee data is based on information from people who have self-reported their past or current employments at DURECT. The data on this page is also based on data sources collected from public and open data sources on the Internet and other locations, as well as proprietary data we licensed from other companies. Sources of data may include, but are not limited to, the BLS, company filings, estimates based on those filings, H1B filings, and other public and private datasets. While we have made attempts to ensure that the information displayed are correct, Zippia is not responsible for any errors or omissions or for the results obtained from the use of this information. None of the information on this page has been provided or approved by DURECT. The data presented on this page does not represent the view of DURECT and its employees or that of Zippia.
DURECT may also be known as or be related to DURECT, DURECT CORP, DURECT Corp., DURECT Corporation, Durect, Durect Corp. and Durect Corporation.